A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

To evaluate the effect on PVR in WHOfunctional class II-III PAH participantstreated with sotatercept plus SOCcompared with placebo plus SOC

Study-ID: 2017-004738-27

DZL Disease Area: PH

Study Type: Interventional

DZL Role: DZL recruiting center, DZL on steering board

Funding: Externally - industry

DZL Participating Sites: BREATH

Start Date: 02.12.2021

Completion Date: 28.06.2022

Status: Closed

DZL recruiting center, DZL on steering board

Disease: Pulmonary Hypertension (PH)

EUCT/CTIS Number: 2017-004738-27